Pfizer Gains New Commercial Drug Orgovyx In Deal With Myovant
Deal Brings Pfizer Another Prostate Cancer Offering
Executive Summary
Myovant's Orgovyx was just approved by the US FDA for prostate cancer and could be approved soon for two women's health indications.
You may also be interested in...
Deal Watch: Celgene CVR From BMS Buyout Falls Through
Another victim of the COVID-pandemic, Celgene's $9-per-share contingent value right tied to BMS obtaining approval of three drugs goes unrealized due to FDA travel restrictions slowing down site inspections. Clene goes public, United Therapeutics buys PRV from Y-mAbs.
Keeping Track: Myovant, Almirall, MacroGenics Nab Novel Approvals; Novartis’ Inclisiran Delayed
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Pfizer Oncology Pipeline Shows Pivot To Targeted Therapies
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports